Co-Authors
This is a "connection" page, showing publications co-authored by ALEXANDER LAZAR and RUSSELL BROADDUS.
Connection Strength
0.627
-
Nuclear ?-catenin localization and mutation of the CTNNB1 gene: a context-dependent association. Mod Pathol. 2018 10; 31(10):1553-1559.
Score: 0.160
-
How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments? J Natl Compr Canc Netw. 2016 06; 14(6):787-92.
Score: 0.139
-
Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. Arch Pathol Lab Med. 2021 11 01; 145(11):1405-1412.
Score: 0.051
-
Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathol. 2021 05; 129(5):374-382.
Score: 0.047
-
Challenges in next generation sequencing analysis of somatic mutations in transplant patients. Cancer Genet. 2018 10; 226-227:17-22.
Score: 0.040
-
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21.
Score: 0.033
-
Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
Score: 0.032
-
Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol. 2015 May; 42(5):308-17.
Score: 0.032
-
Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2644-51.
Score: 0.032
-
Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014 Nov 01; 20(21):5527-36.
Score: 0.031
-
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
Score: 0.031